Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    EHA Jane Apperley





    Treatment Outcomes on Bosutinib: Data from the Real World
    Jane Apperley, Imperial College, London, UK

    • Change in CML survival over time: German studies 
    • Patient pathways for tyrosine kinase inhibitors
    • Introduction of bosutinib into clinical practice
    • Real-World use of bosutinib: UK & Netherlands
    • Responses to bosutinib in chronic phase
    • Reasons for discontinuation of bosutinib
    • Disease progression
    • Adverse events on bosutinib
    • Overall survival
    • Summary and conclusions

    This presentation is adapted from one given during the industry sponsored symposium at EHA.